Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.3052W HIGH $7.44
Volume
10.84 K
Value Traded
27.54 K
Short % Float
4.45%
-7.9%Week
-41.07%1 Month
+878.23%3 Month
+511.48%6 Month
-94.59%5 Year
-91.99%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
11.75 M
EPS (TTM)
-5.78
P/E Ratio
-
Ent. Value
38.73 M
Total Shares
3.15 M
Float Shares
2.71 M
Insiders
14.02%
Institutions
25.61%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CTSO Catalyst Timeline
Dated clinical, regulatory and corporate events for Cytosorbents Corporation
Past FDA Catalysts and PDUFA Decisions
How CTSO actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F19 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Top 96%
Micro Cap(rank 632 of 658)
Percentile Rank
Cytosorbents Corporation has significant pipeline risk (19/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|
Clinical Trial Results
Readouts, endpoints and source filings for every CTSO program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| DrugSorb-ATR Breakthrough | cardiac surgery | 2025-09-29 | first randomized controlled trial data demonstrating that intraoperative use of DrugSorb™-ATR significantly reduces levels of direct oral anticoagulants (DOACs); significant reductions in severe bleeding complications compared with patients treated with aspirin + Plavix (clopidogrel) without CytoSorbRead More | CytoSorbents to Showcase Pioneering New Cardiac Surgery Data in Key Applications at the EACTS 2025 Annual Meeting in CopenhagenRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Chan Phillip P.Director, Officer (Chief Executive Officer) | Buy | 3,774 100,996 held | $6.00 | 09/15/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CTSO
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Redmile Group, LLC | 0 % | 612.00 K | 181.64 K | -31.81% ( -84.73 K) |
CTSO Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CTSO ranks across every disease it competes in
Competitive Position is a premium feature
See how CTSO ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCTSO News
CTSOCytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
CytoSorbents Corporation announced that it will present new clinical data on its CytoSorb technology at two major upcoming international conferences: the EACTS Annual Meeting in Barcelona and the ESICM Annual Congress in Lisbon. The presentations will focus on the use of CytoSorb in cardiac surgery and critical care, addressing critical medical needs such as hyperinflammation and organ dysfunction. The company emphasizes its commitment to expanding the evidence base for CytoSorb through ongoing clinical research.
Read more →CTSO▼ -7.7%on this news· ran to -24% by day 3
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
CytoSorbents Corporation has successfully regained compliance with Nasdaq's minimum bid price requirement of $1.00 per share, following a closing bid price above this threshold for ten consecutive trading sessions. The company aims to further comply with Nasdaq's Capital Market listing requirements by addressing the minimum Market Value of Listed Securities. CEO Dr. Phillip Chan emphasized ongoing efforts to enhance company visibility and achieve operational goals, including advancing their products towards regulatory approval.
Read more →CTSOCytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CytoSorbents Corporation will participate in the H.C. Wainwright 28th Annual Global Investment Conference on September 14-16, 2026. CEO Dr. Phillip Chan and CFO Peter Mariani will engage in a fireside chat and hold one-on-one meetings with investors. The conference will take place in New York City, highlighting the company's advancements in blood purification technologies.
Read more →CTSO▼ -8.8%on this news
CytoSorbents Announces Reverse Stock Split
CytoSorbents Corporation announced a one-for-twenty reverse stock split of its common stock, effective September 8, 2026. This decision, approved by shareholders, aims to increase the stock price to meet Nasdaq's minimum bid requirement. The split will proportionately reduce the number of shares outstanding but is not expected to affect the overall market capitalization.
Read more →CTSO▲ +13.6%on this newsshared move
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
CytoSorbents Corporation announced a patient-level matched analysis showing a 37% reduction in severe bleeding among CABG patients on ticagrelor when using CytoSorb. The findings, presented at the ESC Congress 2026, support a new FDA De Novo submission for DrugSorb-ATR. Recent FDA meetings provided positive feedback on regulatory pathways for the device's use in urgent cardiac surgeries.
Read more →CTSO▼ -9.7%on this news
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents Corporation reported its second quarter 2026 financial results, revealing unchanged revenue of $9.6 million but improved gross margins and reduced operating losses. The company highlighted four key drivers for future growth, including achieving operating cash flow breakeven and expanding into the U.S. market with DrugSorb-ATR. Despite a net loss, the company remains focused on improving operational execution and shareholder value.
Read more →CTSO▲ +5.6%on this news
CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its second quarter 2026 financial results and recent business highlights on August 6, 2026. The company will host a live conference call and webcast at 4:30 PM ET. CytoSorbents specializes in blood purification technologies for critical care, with its lead product CytoSorb approved in the EU and used in over 70 countries.
Read more →CTSO▼ -8.1%on this news
CytoSorbents to Present at the Life Sciences Forum on June 24, 2026 and Meet Virtually with Investors on June 30, 2026
CytoSorbents Corporation (NASDAQ: CTSO) announced that Dr. Phillip Chan, CEO, will present at the Life Sciences Forum on June 24, 2026. Following the presentation, the company will host a Q&A session and has scheduled one-on-one meetings with investors on June 30, 2026. CytoSorbents focuses on blood purification treatment technologies for critical illnesses, and their flagship product, CytoSorb, is approved in the EU and used worldwide. However, the company is still pursuing necessary regulatory approvals in the U.S. and Canada.
Read more →CTSOCytoSorbents Reports First Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
CytoSorbents Corporation reported its financial results for Q1 2026, showing a 2% increase in revenue to $8.9 million. The company experienced a net loss of $5.1 million, attributed largely to foreign currency fluctuations. Despite challenges, including geopolitical issues affecting sales in the Middle East, the company is focused on improving operational efficiency and pursuing FDA submissions for its DrugSorb-ATR device.
Read more →CTSOCytoSorbents to Report First Quarter 2026 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its first quarter 2026 financial results on May 13, 2026. The company is known for its blood purification technologies used in critical care and cardiac surgery. A live conference call will follow the report, allowing for a Q&A session. CytoSorbents has received FDA Emergency Use Authorization for its products in COVID-19 treatment.
Read more →CTSO▼ -10.6%on this news
CytoSorbents Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation reported a 4% increase in sales for 2025, reaching $37.1 million, despite a 10% decline in Germany. The company achieved over 300,000 cumulative CytoSorb treatments globally and is making progress with the FDA on DrugSorb-ATR. The CEO highlighted a focus on improving clinical outcomes and achieving cash flow breakeven in 2026.
Read more →CTSOCytoSorbents Announces HotSwap™ Launch, Renewed Aferetica Partnership, and New Clinical Evidence at ISICEM 2026
CytoSorbents Corporation has announced significant advancements at ISICEM 2026, including the launch of HotSwap™, a new system for rapid blood purification device exchanges. The company also renewed its partnership with Aferetica, enhancing its distribution in Italy. Additionally, new clinical evidence presented reinforces the efficacy of CytoSorb therapy in treating critical conditions.
Read more →CTSOCytoSorbents to Report Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation will report its fourth quarter and full year financial results for 2025 on March 25, 2026. The company specializes in blood purification technologies used in critical care. A live presentation will follow the report, with an archived recording available later. CytoSorbents is also pursuing FDA approval for its DrugSorb-ATR system.
Read more →CTSOCytoSorbents Reports Preliminary Unaudited Fourth Quarter and Full-Year 2025 Results and Business Update
CytoSorbents Corporation reported preliminary unaudited financial results for the fourth quarter and full-year 2025, expecting approximately $9.2 million in Q4 revenue and $37.0 million in total revenue for the year. The company is set to engage with the FDA for a De Novo Application regarding DrugSorb®-ATR, with regulatory approval anticipated in mid-2026. Notably, the results of the pivotal STAR-T study have been accepted for publication, highlighting the clinical significance of their technology within cardiac surgery. Additionally, CytoSorbents has reached a milestone of over 300,000 treatments delivered globally.
Read more →CTSO▼ -12.3%on this news
CytoSorbents to Participate in a Virtual Fireside Chat with D. Boral Capital on Monday, December 15, 2025
CytoSorbents Corporation announced that CEO Dr. Phillip Chan and CFO Peter J. Mariani will participate in a virtual fireside chat with D. Boral Capital on December 15, 2025. The discussion will focus on the company's recent financial performance, regulatory advancements for DrugSorb-ATR, and future growth prospects. This event follows a strong earnings report highlighting significant sales and a robust balance sheet.
Read more →CTSO▼ -5.3%on this news
Updated: CytoSorbents to Present at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation will present at the Jefferies Global Healthcare Conference from November 17-20, 2025, in London. The presentation is scheduled for November 18 at 12:30 PM GMT. This announcement updates previous communications regarding the event and highlights the company's innovative blood purification technologies used in critical care settings.
Read more →CTSOCytoSorbents Reports Third Quarter 2025 Financial Results and Provides Business Update
CytoSorbents Corporation reported strong financial results for Q3 2025, with record sales and improved margins, despite a decline in the German market. The company is implementing a workforce reduction plan to achieve cash flow breakeven by Q1 2026. Additionally, they amended their credit agreement to strengthen their balance sheet and support their regulatory submission for DrugSorb-ATR.
Read more →CTSOCytoSorbents to Participate at the Jefferies Global Healthcare Conference in London
CytoSorbents Corporation, a leader in blood purification technology for life-threatening conditions, will participate in the Jefferies Global Healthcare Conference in London on November 18-19, 2025. CEO Dr. Phillip Chan and CFO Mr. Peter Mariani will hold one-on-one meetings with investors at this notable event. The conference is significant for fostering discussions among executives, investors, and strategists across the healthcare industry, covering various sectors including biotech and medical technology. CytoSorbents' proprietary technologies offer critical applications in intensive care, especially during cardiothoracic surgery.
Read more →CTSOCytoSorbents to Report Third Quarter 2025 Financial Results and Recent Business Highlights
CytoSorbents Corporation is set to report its third quarter 2025 financial results and recent business highlights on November 13, 2025. The company, known for its blood purification technologies, is actively pursuing regulatory approvals for its products while emphasizing its commitment to treating life-threatening conditions. Health care professionals and stakeholders can participate in a live conference call and webcast to gain insights into the company's operational developments and future outlook.
Read more →About Cytosorbents Corporation
Headquarters305 COLLEGE ROAD EAST, PRINCETON, NJ, 08540
BIOPHARMAWATCH ELITE PLUS
Trade the next CTSO catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime